Table 2.

Effects of Kangshuanling sublingual tablet on CD62P and CD63, TXA2, platelet aggregation rate (PAR) and thrombosis length (TL) in vitro in UC patients (mean ± SD)

Group	CD62p (%)	CD63 (%)	TXA2 (ng/L)	PAR (%)	TL (cm)
UC patients
Pre-treatment	8.0 ± 3.1b	6.3 ± 2.1b	548.2 ± 84.9b	43.2 ± 10.1b	2.3 ± 0.6b
Post-treatment	4.1 ± 1.8a,d	3.2 ± 1.6a,d	390.1 ± 67.0d	34.8 ± 8.1d	1.8 ± 0.3d
Normal controls	1.9 ± 0.4	1.6 ± 0.8	340.2 ± 40.4	34.1 ± 9.1	1.7 ± 0.4

^aP < 0.05,

^bP < 0.01 vs normal controls;

^dP < 0.01 vs pretreatment.